MyStart Health

What the MyStart Health Intake Looks Like

We walked through MyStart Health’s full intake ourselves, from the opening BMI calculation through the 33-screen medical history, a final attestation, and a hard government-issued photo ID + selfie verification before eligibility is finalized. This is the most rigorous written intake in our catalog.

MyStart is the only platform in our catalog that hard-gates eligibility on a live government-issued photo ID plus selfie verification. At the end of the Eligibility section, the intake offers three verification paths — a QR code scan, an SMS link delivered to the patient’s phone, or a desktop camera option — and the patient cannot finalize eligibility without completing one. This is standard for financial services onboarding but rare in telehealth intake. It adds meaningful friction, and it meaningfully reduces the risk of identity fraud and intake-form abuse.

The thyroid cancer screen reads: “Do you have a personal or family history (grandparents, parents, siblings, or children) of thyroid cancer?” Most GLP-1 intakes that ask about family history define it narrowly (parents and siblings). MyStart’s inclusion of grandparents and children in the family definition is broader than the category norm and closer to what an obesity-medicine clinician would actually want to see. Paired with the separate personal-or-family MEN gate earlier in the flow, this is among the strongest MTC/MEN safety screens we’ve seen.

MyStart includes a dedicated screen asking specifically whether the patient is on Sotalol or Flecainide — cardiac antiarrhythmics with known narrow-therapeutic-index interactions when gastric emptying changes. It also flags Levodopa, Digoxin, and Lithium as specific concomitant-medication gates in the main contraindication list. No other platform in our catalog names these drugs by molecule; most defer all drug-interaction checks to the live clinician or a generic “are you on any other medications” field. Naming the specific high-risk molecules turns drug interaction screening into a front-loaded safety gate rather than a post-hoc review.

Even at this rigor level, the intake does not include a validated PHQ-2 or PHQ-9 depression instrument (eating disorder and substance use are the only mental-health-adjacent gates), does not ask the patient to self-report blood pressure or resting heart rate, and does not expose pricing in the captured flow — final cost is disclosed after eligibility is approved in the provider follow-up. There is no stand-alone numeric phone OTP step, though the ID verification can be delivered via SMS link and functions as a soft phone check.

Before the intake submits, MyStart requires an explicit acknowledgment: “I acknowledge that all of the information I have provided is accurate and up to date to the best of my knowledge. I understand that providing false or incomplete information could result in improper medical treatment, which may lead to serious illness or death.” That language — “serious illness or death” — is blunter than the industry norm and is a fair summary of the stakes for anyone concealing a contraindication in a GLP-1 intake. A few lines up the form, the safety acknowledgment reminds the patient that “clinicians must confirm a valid medical need for compounded GLP-1 therapy” and that even minor conditions should be disclosed. This is as aggressive as self-attestation gets in our catalog.

Opens mystarthealth.com in a new tab. We may earn a commission if you start treatment through this link, at no additional cost to you.